Crossmark

Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients

Crossref DOI link: https://doi.org/10.1186/s12920-019-0481-z

Published Online: 2019-03-13

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lavrov, Alexander V. https://orcid.org/0000-0003-4962-6947
Chelysheva, Ekaterina Yu. https://orcid.org/0000-0001-6423-1789
Adilgereeva, Elmira P. https://orcid.org/0000-0002-6440-0500
Shukhov, Oleg A. https://orcid.org/0000-0001-5393-0816
Smirnikhina, Svetlana A. https://orcid.org/0000-0002-1558-3048
Kochergin-Nikitsky, Konstantin S. https://orcid.org/0000-0002-0096-4542
Yakushina, Valentina D. https://orcid.org/0000-0001-5236-9297
Tsaur, Grigory A. https://orcid.org/0000-0002-9881-6221
Mordanov, Sergey V. https://orcid.org/0000-0001-7924-4945
Turkina, Anna G. https://orcid.org/0000-0001-9947-2371
Kutsev, Sergey I. https://orcid.org/0000-0002-3133-8018
License Information

Text and Data Mining valid from 2019-03-01
More Information

Article History

First Online: 13 March 2019

Ethics approval and consent to participate

: Not applicable

: Not applicable

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.